INDIA’S top pharmaceuticals export group said the government’s curbs on some drug exports amid the spreading coronavirus outbreak has caused panic in Europe and will “severely impact” businesses in the sector.
India, the world’s main supplier of generic drugs, has restricted the export of 26 active pharmaceutical ingredients (APIs) and the medicines made from them, in a move seen aimed at tackling possible domestic shortages of medicine during the outbreak.
On Wednesday (4), Dinesh Dua, chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), told that some of the restricted APIs and medicines were widely exported to Europe and the US.
“I am getting a huge number of calls from Europe because it is very sizeably dependent on Indian formulations and we control almost 26 per cent of the European formulations in the generic space. So they are panicking,” Dua said.
India’s list of restricted medicines account for 10 per cent of its total pharmaceutical exports and includes several antibiotics, as well as Paracetamol, a common pain reliever also sold as acetaminophen.
The Food and Drug Administration in the US, where Indian imports accounted for 24 per cent of medicines in 2018, said on Tuesday (3) it was working to determine how the restrictions will affect US supplies.
The restrictions could hurt India’s image as a pharmacy to the world and would impact shipments which were already lined up for export at warehouses and ports, Pharmexcil argued in a letter to India’s Directorate General of Foreign Trade (DGFT).
The DGFT did not respond to a request for comment.
“The exporters not only suffer the monetary losses but also their credibility and reputation in international market is at stake,” said the letter, which urged the government to allow exports of drugs manufactured before the restrictions kicked in.
“(This) would severely impact our members.”
Dua told there were $10 million worth of drugs currently at Indian ports or close to being readied for export.
Pharmexcil counts dozens of pharmaceutical firms such as Pfizer Ltd and Abbott among its members. The council falls under the federal commerce ministry.
Novartis AG said on Wednesday it was monitoring the changes in Indian export policy and will “adapt measures as the situation evolves”, though the company does not anticipate a supply chain disruption as of now.
Indian drugmakers rely on China, the source of the virus outbreak, for almost 70 per cent of the APIs for their medicines. Industry experts say they are likely to face shortages if the coronavirus epidemic drags on.
India – which has so far confirmed 28 cases of the coronavirus, including 16 Italians – has urged calm and said there were enough stocks to manufacture formulations for two to three months.
(Reuters)
